The clinical and endoscopic efficacy of infliximab and quality of life of patients were evaluated by follow-up of 30 weeks. If a patient is failure to adhere to medication, the end point for the observation is 4 weeks after treatment. Crohn’s disease activity index (CDAI), simple endoscopy score of Crohn’s disease (SESCD) were assessed

before and after treatment. Several predictors, including CRP, SR, ANCA/ASCA, mucosal TNFα and TNFα mRNA were tested. Results: 7 cases of 12 patients are non-strictured and non-penetrating, the other four cases is penetrating. Fistula associated with 5 cases of 10 active patients. There are 2 patients with Crohn’s disease in remission (one with severe lower gastrointestinal bleeding caused by CD, the PLX3397 cell line other with peripheral arthritis associated with enteropathy). After 2 weeks of treatment, among those 10 patients with Selleckchem Dabrafenib active CD, 6 cases presented effective response (60%); the fistula in one of the 5 patients with fistula have become healed; and the patient with peripheral arthritis associated with enteropathy has improved. At the end of observation, clinical remission was found in 5 patients (the

rate of remission is 50%) and 2 cases had clinical response; the two patients with remission remained in remission, one patient with severe lower gastrointestinal bleeding caused by CD were in control of bleeding and absence of further recurrence by 30 weeks follow-up, the symptoms associated with peripheral arthritis have disappeared. 上海皓元医药股份有限公司 At the end of follow-up, endoscopy was performed in 9 patients to evaluate the healing of mucosal ulceration, with ulcers in 3 cases basically healing, and ulcers in other 6 cases becoming smaller in size and less in number. Adverse events were seen in 4 out of 12 patients with infiiximab treatment, among whom two case with leukopenia gets recovery after stopping infliximab, the other two suffered severe Varicella and Herpes Zoster, respectively, and both of them are cured after anti-virus therapy. We use SF-12 to evaluate quality of life, which has improved after

treatment. Age, disease duration, CDAI, SESCD, CRP, SR, ANCA/ASCA and mucasal TNFα did not predict clinical remission. There was an inverse association between pre-treatment TNFα mRNA expression levels and clinical response of IFX treatment. Conclusion: Infliximab is effective in the induction and maintenance of remission and fistula healing, with low incidence of adverse events. The clinical outcome of IFX teatment was inversely associated with the pre-treatment gene expression levels of TNFα in colorectol mucosa. However, its long-term efficacy, safety and real independent predictor need further studies with large patients to confirm. Key Word(s): 1. infliximab; 2. Crohn’s disease; 3. efficacy; 4.